0.29 USD
▼+0.01-3.68%
盘后 0.30 -2.16%
2026-08-03
市值
$1.86M
市盈率
—
EPS
-1.94
股息率
—
52 周区间
0.23 – 3.09
成交量
1.09M
Beta
1.71
目标价
—
52W 低 0.2352W 高 3.09
价格走势
公司简介
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as preventi...